

Valeant Pharmaceuticals International, Inc.  
Form 8-K  
November 14, 2017

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of the earliest event reported): November 14, 2017 (November 14, 2017)**

**Valeant Pharmaceuticals International, Inc.**

**(Exact Name of Registrant as Specified in Its Charter)**

**British Columbia, Canada  
(State or Other Jurisdiction of  
Incorporation or Organization)**

**001-14956  
(Commission  
File Number)  
2150 St. Elzéar Blvd. West**

**98-0448205  
(I.R.S. Employer  
Identification Number)**

**Laval, Quebec**

**Canada H7L 4A8**

**(Address of Principal Executive Offices)(Zip Code)**

**514-744-6792**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

*Pricing of Secured Notes Offering*

On November 14, 2017, Valeant Pharmaceuticals International, Inc. issued a press release announcing that, on November 14, 2017, it had priced its offering of \$750 million aggregate principal amount of 5.500% senior secured notes due 2025 (the "notes"). The notes will be additional notes and form part of the same series as the Company's existing 5.500% senior secured notes due 2025.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Press Release announcing the pricing of the secured notes offering, dated November 14, 2017.

**EXHIBIT INDEX**

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	<u>Press Release announcing the pricing of the notes offering, dated November 14, 2017.</u>

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS  
INTERNATIONAL, INC.

By: /s/ Paul S. Herendeen

Name: Paul S. Herendeen

Title: Executive Vice President and  
Chief Financial Officer

Date: November 14, 2017